Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
1376614 | Bioorganic & Medicinal Chemistry Letters | 2008 | 5 Pages |
Abstract
A computer-aided drug design strategy leads to the identification of a new class of p38 inhibitors based on the 2-tolyl-(1,2,3-triazol-1-yl-4-carboxamide) scaffold. The tolyl triazole amides provided a potent platform amenable to optimization. Further exploration leads to compounds with greater than 100-fold improvement in binding affinity to p38. Derivatives prepared to alter the physicochemical properties produced inhibitors with IC50’s in human whole blood as low as 83 nM.
Graphical abstractThe de novo design and synthesis of a novel class of potent and selective p38 MAPK inhibitors is described.Figure optionsDownload full-size imageDownload as PowerPoint slide
Related Topics
Physical Sciences and Engineering
Chemistry
Organic Chemistry
Authors
D.A. Cogan, R. Aungst, E.C. Breinlinger, T. Fadra, D.R. Goldberg, M.H. Hao, R. Kroe, N. Moss, C. Pargellis, K.C. Qian, A.D. Swinamer,